SCHEMBL1375465

SCHEMBL1375465

CC(C)(C)OC(=O)N1C[C@H](O)C[C@H]1C(=O)Nc1ccc(Oc2ccc(F)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.57
POLB P06746 3/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
HDAC8 Q9BY41 3/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
NPC1 O15118 1/20 0.49
S1PR1 P21453 8/20 0.47
CYP2C9 P11712 6/20 0.47
CYP2D6 P10635 6/20 0.47
S1PR2 O95136 1/20 0.43
CFTR P13569 1/20 0.42
PTPN2 P17706 1/20 0.42
PTPN1 P18031 1/20 0.42
PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1375463 1.00 CYP3A4 (0.57) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL7728024 0.91 MEN1 (0.62) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL7728781 0.91 MEN1 (0.62) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL7728020 0.91 MEN1 (0.62) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL1372122 0.86 HDAC8 (0.49) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL1372124 0.86 HDAC8 (0.49) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL30129963 0.84 MEN1 (0.67) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL13325458 0.83 POLB (0.61) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL13359602 0.82 POLB (0.60) CYP3A4POLBCYP1A2CYP2C19HDAC8
SCHEMBL7728565 0.81 MEN1 (0.51) CYP3A4POLBCYP1A2CYP2C19HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791102-B2 Acetanilide sphingosine-1-phosphate receptor antagonists EXELIXIS, INC. (US) 2014-07-29 US disclosed
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists EXELIXIS, INC. (US) 2011-11-24 US disclosed
EP-2346821-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS Exelixis, Inc. (US) 2011-07-27 EP disclosed
WO-2010045580-A1 SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS EXELIXIS, INC. (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288076-A1 Sphingosine-1-Phosphate Receptor Antagonists S1PR1, S1PR2, S1PR3 CYP3A4 4784/4885POLB 2626/4885CYP1A2 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.